Hook & Thesis
Oscar Health (OSCR) has shifted the conversation: once a buzzy insurtech growth story, it is now a scaled operator with nearly 3 million members and improving medical economics. The company raised 2026 operating earnings guidance to $500M-$700M and is guiding revenue near $18.7B-$19B. Those are the kind of numbers that can shift investor perception from a high-volatility growth name to a fundamentally profitable insurance operator, and that shift is what I expect to drive a formal rerating into 2027.
In short: buy on current weakness with the expectation that continued membership expansion, a medical loss ratio (MLR) improvement and disciplined pricing will push multiples higher next year. The trade below is a long, risk-managed position sized to tolerate headline volatility while giving the story time to materialize over the next 180 trading days.
What Oscar Does and Why the Market Should Care
Oscar Health is a managed-care company built on a technology platform. It offers individual and family plans, small group coverage and Medicare Advantage products, and it sells technology services to payors and providers. The business is interesting to investors because it blends recurring premium revenue and membership scale with a technology-led cost structure that can compress SG&A over time.
Investors should care because Oscar is showing the two things insurers need to be taken seriously: scale and improving underwriting. Membership was reported at roughly 2.96 million, up 46.2% year-over-year, and Q2 revenue beat with $4.9B (up 70.4%). The company has also materially improved its medical loss ratio to 75% from 83% and reduced SG&A to 14.7% from 17.2% via technology-driven efficiencies. Those are not transitory noise items — they move operating leverage and cash flow materially.
Numbers That Support the Case
- Revenue guidance: company 2026 revenue guidance sits in the $18.7B-$19.0B range.
- Operating earnings guide: management raised 2026 operating earnings to $500M-$700M (previously $250M-$450M), citing improved MLR and disciplined pricing.
- Q2 momentum: revenue of $4.9B (+70.4% YoY) and membership of 2.96 million (+46.2% YoY).
- Medical economics: MLR improved to 75% versus 83% previously, and SG&A fell to 14.7% from 17.2% — a swing that supports operating margin expansion.
- Capital and valuation: market capitalization is roughly $10.3B with enterprise value near $6.95B, giving an EV/sales of ~0.46 and a price-to-sales of ~0.7. Free cash flow sits at about $4.38B on the reported basis, reflecting improving cash generation.
Valuation Framing
Oscar is trading at a mid-single digit EV/sales multiple and a P/E in the high teens to low 20s depending on the metric used. For a scaled insurer with improving loss ratios and a potential path to sustained operating profitability, an EV/sales of ~0.46 and price-to-sales of ~0.7 appear conservative relative to the upside if operating margins normalize towards the mid-single-digit to low-double-digit percent range.
Put another way: the market is effectively valuing Oscar at less than one turn of sales despite membership growth of nearly 50% YoY and a meaningful improvement in underwriting. If Oscar converts guidance into consistent operating earnings and margins hold, market multiple expansion is a logical next step — hence the rerating thesis for 2027.
Catalysts
- Quarterly results and management commentary on 11/05/2026: Analysts expect the next print to confirm margin progress and revenue cadence; clearer guidance or outperformance would accelerate a rerate.
- Enrollment and churn updates during open enrollment: management highlighted 2%-4% monthly churn headwinds; stabilization or improvement here will directly improve lifetime value economics.
- Further margin progress: continued MLR improvement (below 75%) and SG&A leverage would translate to higher operating earnings and improved cash flow.
- Capital deployment updates: with a strong capital base cited near $10.2B, deployment into share buybacks, strategic M&A or tech investments could change investor emphasis from growth-to-scale to cash return.
- Analyst estimate upgrades: several analysts have already moved estimates higher; continued revisions and a steady beat-and-raise pattern would supply multiple expansion fuel.
Trade Plan (actionable)
Direction: Long
Entry Price: $33.42
Target Price: $48.00
Stop Loss: $28.00
Horizon: long term (180 trading days)
Rationale for the trade plan: at current equity value near $33.42 the stock prices in much of the growth story but not the margin improvement. A rally to $48 implies a multiple expansion and re-rating consistent with Oscar transitioning toward stable operating earnings and improved perceptions among institutional investors. The 180 trading day horizon gives time for quarterly prints (including the 11/05/2026 report) and the open enrollment cycle to influence membership and churn trends.
Technical & Market Context
Technicals show a constructive backdrop: 10-day SMA is around $33.06, 20-day SMA $31.69 and the MACD is showing bullish momentum with a positive histogram. Short interest is present but modest relative to liquidity; days-to-cover is in the low single digits, which means rapid moves could happen but short squeezes are not a dominant structural risk.
Risks and Counterarguments
Below are the primary risks that could invalidate the thesis or cause the trade to underperform. Each risk is paired with how I would monitor it.
- Rising medical costs and reserve pressure. If medical inflation re-accelerates or favourable reserve items stop repeating, the MLR could widen back toward prior levels. Monitor sequential MLR and commentary on inflation and provider reimbursement trends.
- Higher-than-expected churn during open enrollment. Management highlighted 2%-4% monthly churn in the back half of the year. If churn accelerates beyond guidance, membership growth — the foundation of the revenue story — could weaken. Watch enrollment numbers and retention metrics closely.
- Execution risk on technology and SG&A leverage. Oscar’s margin story depends on tech-driven efficiency. If customer acquisition costs or SG&A creep higher due to competitive pressures, operating leverage will be muted.
- Valuation is already forward-looking. The stock trades at a premium on some forward metrics versus legacy peers. Any miss in growth or margins could trigger outsized downside from a sentiment-driven sell-off.
- Regulatory risk. Changes in ACA rules, Medicaid passthroughs or Medicare Advantage regulation could materially change unit economics. Track policy developments and regulatory commentary.
- Macro shock or market multiple compression. Broader market risk-off could reduce appetite for growth-and-transition stories even if Oscar posts decent numbers.
Counterargument: A credible counterargument is that much of Oscar’s improvement is seasonal or the result of one-off reserve releases and that true sustainable underwriting profitability is farther out. If the company’s improved MLR proves temporary — or if improved earnings are driven primarily by favorable reserve adjustments rather than underlying claims trends — the rerating will not materialize and multiples could compress. I will flag sustained sequential MLR improvement and repeated operating earnings beats as evidence that the improvements are structural, not cyclical.
What Would Change My Mind
I would reduce or exit the position if any of the following occur: (1) a single quarter shows a re-widening MLR back above ~80% without credible management explanation; (2) membership growth stalls or churn accelerates materially above management commentary; (3) guidance is pulled or lowered for 2027 operating earnings; or (4) the company signals material deterioration in claim trends or a rise in capital needs that forces a deleveraging of shareholder-friendly actions.
Conclusion
Oscar Health is no longer just a growth story to be judged on flashy metrics — it now has scale, improving medical economics and a capital base. Those elements justify a measured long position that anticipates a rerating in 2027 if the company sustains margin improvements and churn stabilizes through the open enrollment cycle. The trade laid out above balances upside potential against concrete downside protection and a time frame that permits macro and executional noise to settle. Take the position sized to your risk tolerance and monitor the MLR, churn and operating earnings cadence closely.
Trade checklist to watch: membership trends, MLR trajectory, SG&A leverage, guidance cadence, and capital deployment updates.